Iovance Biotherapeutics, Inc. IOVA Short- and long-term operating lease liabilities
Short- and long-term operating lease liabilities at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s short- and long-term operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s short- and long-term operating lease liabilities?
- Iovance Biotherapeutics, Inc. (IOVA) reported short- and long-term operating lease liabilities of -$2.03M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s short- and long-term operating lease liabilities changed year-over-year?
- Iovance Biotherapeutics, Inc.'s short- and long-term operating lease liabilities increased by 34.9% year-over-year, from -$3.11M to -$2.03M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s short- and long-term operating lease liabilities?
- Over 4 years (2021 to 2025), Iovance Biotherapeutics, Inc.'s short- and long-term operating lease liabilities has grown at a 16.7% compound annual growth rate (CAGR), from -$5.88M to -$10.9M.